Novartis axes blood cancer drug
31 Jan 2024
Phase 3Fast TrackFinancial StatementClinical ResultClinical Trial Termination
In a financial report, Novartis revealed that its anti-TIM-3 antibody, sabatolimab, failed a crucial phase 3 blood cancer trial.
The study, focusing on patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia-2, showed no survival improvement with azacitidine plus sabatolimab (MBG453) compared to placebo. Consequently, Novartis has halted sabatolimab's development.
Sabatolimab is a therapeutic agent designed to target the TIM-3 protein, a cell surface receptor involved in regulating the immune response. By inhibiting TIM-3, sabatolimab aims to enhance the anti-tumor immune response, particularly in cancer cells expressing TIM-3.
In 2021, the FDA granted fast track designation to the therapy for the treatment of adult patients with MDS characterized by a high or very high IPSS-R risk category when combined with hypomethylating agents.
MDS, a group of rare and often underdiagnosed blood cancers, is marked by a compromised immune system and the proliferation of leukemic stem cells. Despite recent treatment innovations like hypomethylating agents in higher-risk MDS, patients still face poor outcomes, including limited response duration and a median overall survival rate of less than a year.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.